Miners A H, Sabin C A, Mocroft A, Youle M, Fisher M, Johnson M
Health Economics Research Group, Brunel University, Uxbridge, London.
HIV Clin Trials. 2001 Nov-Dec;2(6):484-92. doi: 10.1310/48ET-TT7G-35RA-D4C3.
To compare health-related quality of life (HR-QOL) in individuals infected with HIV to general population levels and to assess the relationship between HR-QOL and markers of disease progression in the era of highly active antiretroviral therapy (HAART).
This was a cross-sectional questionnaire-based study. This study included 154 individuals at least 18 years old with HIV who either were attending a London hospital or were visited by a community team in Brighton. Study participants were asked to complete two HR-QOL questionnaires. This study used HR-QOL, as measured using the Medical Outcome Study HIV Health Survey (MOS-HIV) and EuroQoL self-report (EQ-5D) questionnaires, as the main outcome measure. Responses on the EQ-5D were compared with a published general population data set. The relationships between scores on the MOS-HIV and EQ-5D questionnaires and a number of independent variables including CD4 count and viral load were also assessed.
Each analysis was based on the results of at least 128 questionnaires. The mean MOS-HIV mental and physical component scores were 43.2 (SD = 12.2) and 41.8 (SD = 13.2), respectively. After adjusting for differences in age and gender, it was shown that individuals with HIV reported significantly lower EQ-5D(utility) ( p =.0001) and EQ-5D(VAS) ( p =.0001) compared with the general population. However, further analysis revealed few significant associations between markers of disease progression and HR-QOL.
Individuals with HIV generally recorded significantly lower HR-QOL compared with the general population. Thus, prevention of further transmissions of the virus is still likely to prevent significant morbidity losses in addition to mortality losses, despite the availability of HAART. However, disease progression as measured is not clearly related to further reductions in HR-QOL.
比较感染人类免疫缺陷病毒(HIV)个体的健康相关生活质量(HR-QOL)与一般人群水平,并评估在高效抗逆转录病毒治疗(HAART)时代,HR-QOL与疾病进展标志物之间的关系。
这是一项基于问卷调查的横断面研究。该研究纳入了154名年龄至少18岁的HIV感染者,他们要么在伦敦一家医院就诊,要么接受了布莱顿社区团队的访视。研究参与者被要求完成两份HR-QOL问卷。本研究将使用医学结果研究HIV健康调查(MOS-HIV)和欧洲五维度健康量表自我报告(EQ-5D)问卷测量的HR-QOL作为主要结局指标。将EQ-5D的回答与已发表的一般人群数据集进行比较。还评估了MOS-HIV和EQ-5D问卷得分与包括CD4细胞计数和病毒载量在内的多个自变量之间的关系。
每项分析均基于至少128份问卷的结果。MOS-HIV心理和生理成分得分的平均值分别为43.2(标准差=12.2)和41.8(标准差=13.2)。在调整年龄和性别差异后,结果显示,与一般人群相比,HIV感染者报告的EQ-5D(效用值)(p=0.0001)和EQ-5D(视觉模拟量表)(p=0.0001)显著更低。然而,进一步分析显示,疾病进展标志物与HR-QOL之间几乎没有显著关联。
与一般人群相比,HIV感染者的HR-QOL通常显著更低。因此尽管有HAART,但预防病毒的进一步传播除了可预防死亡损失外,仍可能预防显著的发病损失。然而,所测量的疾病进展与HR-QOL的进一步降低并无明显关联。